Overview

Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke

Status:
Terminated

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of PF-03049423 following multiple dose administration to subjects with ischemic stroke. The study will also evaluate the efficacy of PF-03049423, relative to placebo, in subjects with ischemic stroke following 90 days of therapy. The study will also explore the relationship between PF-03049423 concentration and blood pressure.

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

3-(4-(2-hydroxyethyl)piperazin-1-yl)-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido(3,4-b)pyrazin-2(1H)-one